Literature DB >> 10368301

Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis.

M A McTigue1, J A Wickersham, C Pinko, R E Showalter, C V Parast, A Tempczyk-Russell, M R Gehring, B Mroczkowski, C C Kan, J E Villafranca, K Appelt.   

Abstract

BACKGROUND: Angiogenesis is involved in tumor growth, macular degeneration, retinopathy and other diseases. Vascular endothelial growth factor (VEGF) stimulates angiogenesis by binding to specific receptors (VEGFRs) on the surface of vascular endothelial cells. VEGFRs are receptor tyrosine kinases that, like the platelet-derived growth factor receptors (PDGFRs), contain a large insert within the kinase domain.
RESULTS: We report here the generation, kinetic characterization, and 2.4 A crystal structure of the catalytic kinase domain of VEGF receptor 2 (VEGFR2). This protein construct, which lacks 50 central residues of the 68-residue kinase insert domain (KID), has comparable kinase activity to constructs containing the entire KID. The crystal structure, determined in an unliganded phosphorylated state, reveals an overall fold and catalytic residue positions similar to those observed in other tyrosine-kinase structures. The kinase activation loop, autophosphorylated on Y1059 prior to crystallization, is mostly disordered; however, a portion of it occupies a position inhibitory to substrate binding. The ends of the KID form a beta-like structure, not observed in other known tyrosine kinase structures, that packs near to the kinase C terminus.
CONCLUSIONS: The majority of the VEGFR2 KID residues are not necessary for kinase activity. The unique structure observed for the ends of the KID may also occur in other PDGFR family members and may serve to properly orient the KID for signal transduction. This VEGFR2 kinase structure provides a target for design of selective anti-angiogenic therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10368301     DOI: 10.1016/s0969-2126(99)80042-2

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  38 in total

1.  Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.

Authors:  Titus J Boggon; Yiqun Li; Paul W Manley; Michael J Eck
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

Review 2.  VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy.

Authors:  Nader Rahimi
Journal:  Front Biosci       Date:  2006-01-01

3.  Scoring of KDR kinase inhibitors: using interaction energy as a guide for ranking.

Authors:  Georgia B McGaughey; J Chris Culberson; Bradley P Feuston; Constantine Kreatsoulas; Vladimir Maiorov; Joseph Shpungin
Journal:  Mol Divers       Date:  2006-09-27       Impact factor: 2.943

4.  Leucine motif-dependent tyrosine autophosphorylation of type III receptor tyrosine kinases.

Authors:  Rosana D Meyer; Xiaofeng Qian; Hwai-Chen Guo; Nader Rahimi
Journal:  J Biol Chem       Date:  2006-01-23       Impact factor: 5.157

Review 5.  Overview of protein structural and functional folds.

Authors:  Peter D Sun; Christine E Foster; Jeffrey C Boyington
Journal:  Curr Protoc Protein Sci       Date:  2004-05

6.  A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.

Authors:  Huaibin Chen; Jinghong Ma; Wanqing Li; Anna V Eliseenkova; Chongfeng Xu; Thomas A Neubert; W Todd Miller; Moosa Mohammadi
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

Review 7.  Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.

Authors:  S B Noonberg; C C Benz
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

8.  Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.

Authors:  A Irrthum; M J Karkkainen; K Devriendt; K Alitalo; M Vikkula
Journal:  Am J Hum Genet       Date:  2000-06-09       Impact factor: 11.025

Review 9.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

10.  Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene.

Authors:  Melissa Rotunno; Mary L McMaster; Joseph Boland; Sara Bass; Xijun Zhang; Laurie Burdett; Belynda Hicks; Sarangan Ravichandran; Brian T Luke; Meredith Yeager; Laura Fontaine; Paula L Hyland; Alisa M Goldstein; Stephen J Chanock; Neil E Caporaso; Margaret A Tucker; Lynn R Goldin
Journal:  Haematologica       Date:  2016-06-13       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.